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The microRNA-325 inhibits hepatocellular
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mobility group box 1
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Abstract
Background: MicroRNAs (miRNAs) can serve as tumor suppressors and might provide an efficient strategy for
annihilating tumor cells. Nevertheless, the potential role of miR-325 in hepatocellular carcinoma (HCC) is still unknown.
Methods: Using RT-PCR, immunoblots invasion assays and bioinformatics strategies, we investigated the potential role
of miR-325 in HCC.
Results: We showed that miR-325 was decreased and HMGB1 was increased in 99 patients with hepatocellular
carcinoma. MiR-325 inhibition promoted cell invasion and proliferation, while miR-325 upregulation inhibited cell
invasion and proliferation by using transwell and CCK8 assays. We further showed that HMGB1 might be a direct target
of miR-325 and is negatively regulated by miR-325. Down-regulation of miR-325 predicts poor prognosis for HCC
patients.
Conclusions: These findings implied that miR-325 regulates cell invasion and proliferation via targeting HMGB1 and
may be a potential prognostic marker for HCC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
4655707031717989
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Background
Human hepatocellular carcinoma (HCC), one of the
most common aggressive tumors worldwide has rela-
tively high mortality rate among malignant tumors [1].
The overall 5-year survival rate for HCC is extremely
low (18 %) [1]. Due to the lack of specific early symp-
toms or effective tumor biomarkers, most patients with
HCC are diagnosed at the advanced stages. Even though
there has been great improvement on traditional treat-
ments, such as surgery supplemented with radiotherapy
and chemotherapy, the prognosis of these patients is
very poor. Thus, it is extremely necessary to identify
novel and efficient biomarkers used in the diagnosis and
as therapeutic targets for human HCC.
MicroRNAs (miRNA) are small noncoding RNA mole-
cules that can function as a posttranscriptional factor for
gene expression and determine cell fate by modulating
multiple cellular pathways. The miRNAs may exert their
functions by base-pairing with the 3’-untranslated region
(3’-UTR) of target mRNAs [2]. Deregulated miRNAs are
often indicators of cellular event that contribute to the
onset of malignancy such as tumor [3]. A number of re-
cent in vitro and in vivo studies have identified critical
roles for miRNAs in the regulation of tumor cell inva-
sion, metastasis and migration [4]. One potential reason
that miRNAs are downregulated at many cancer cells is
that they may target multiple oncogenic pathways and
serve as tumor suppressors by inducing apoptosis.
Downregulation of tumor suppressor miRNAs in various
tumor tissues has been extensively reported [5–7].
Apoptosis is a complex process that proceeds through
either intrinsic or extrinsic pathways [8]. The extrinsic
pathway, which is triggered by death-ligand will
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culminate in effector caspase activation [9]. The intrinsic
pathway centers on the mitochondria, which contain key
apoptogenic factors such as cytochrome c, AIF, SMAC/
DIABLO, Htra2/Omi [10]. Once activated, intricate in-
teractions among BCL-2 family members can trigger the
release of these factors and initiate effective apoptotic
program [10].
High mobility group box 1 (HMGB1), the most im-
portant member of the high mobility group box protein
family, is a nuclear protein with different functions in
the cell; it has a role in cancer progression, angiogenesis,
invasion, and metastasis development. For example,
HMGB1 is a newly identified gene overexpressed in
ovarian cancer and associated with poor pathologic features
[11]. Furthermore, Zhang et al. reported that HMGB1
could facilitate lymphangiogenesis, while HMGB1 cocul-
ture with tumor associated macrophages may strengthen
the pro-lymphangiogenic potential [12]. HMGB1 overex-
pression has a significant role in tumor progression
(especially migration of tumor cells) and tumor ability
to metastasize in colorectal cancers. Thus, it corroborates
the idea that it might be an important prognostic factor
[13]. Knockdown of HMGB1 inhibits growth and invasion
of gastric cancer cells through the NF-κB pathway in vitro
and in vivo [14].
In this study, we sought to investigate the potential
role of miR-325 in patients with HCC. Furthermore, we
verified that miR-325 could regulate cells invasion and
proliferation of HCC by targeting HMGB1. Therefore,
miR-325 may be a potential prognostic marker for HCC.
Methods
Clinical samples and statements
All the liver cancer tissues and correspondingly normal ad-
jacent samples were collected from the 99 patients that had
undergone routine surgery at TCM-Integrated Hospital,
Southern Medical University from January 2010 to
November 2013. Total tissues were stored at −80 °C
until RNA extraction. Our study was approved by the
Ethical Committee of TCM-Integrated Hospital, South-
ern Medical University and every patient has written
informed consent, the study methodologies conformed
to the standards set by the Declaration of Helsinki.
Cell culture
The human hepatocellular carcinoma cell lines (SMMC-
7721, Hep3B, HepG2, Huh7 and Bel7404) and normal
liver cell (LO2) were purchased from the Institute of
Biochemistry and Cell Biology of the Chinese Academy
of Sciences (Shanghai, China). All cell lines were cul-
tured in RPMI-1640 medium with 10 % fetal bovine
serum (Invitrogen, Carlsbad, CA) and penicillin (200 U/ml)
at 37 °C with 5 % CO2.
Isolation of total RNA and Quantitative RT-PCR
RNA of all the tumor samples and corresponding adja-
cent tissues was extracted by using TRIzol (Invitrogen,
Carlsbad, CA) and both miRNA and mRNA were re-
versely transcribed to cDNA. MiRNAs expression levels
were detected by using the TaqMan stem-loop qRT-PCR
method with a mirVana miRNA Detection Kit and gene-
specific primers, and normalized to U6. Relative HMGB1
mRNA expression levels were examined by using SYBR
Green quantitative real-time PCR (qRT-PCR). Gene-
pharma synthesized the HMGB1 siRNA. And GAPDH








qRT-PCR assay was performed by using the ABI 7900
Fast Real-Time PCR system (ABI, CA, USA).
Invasion assay
Invasion assays were conducted with BioCoat Matrigel
(BD Biosciences, San Jose, CA) and invasion chambers
(Millipore, Eschborn, Germany) with an 8-μm pore size
according to the manufacturers’ instructions. The chamber
were coated with 200 mg/ml BD Matrigel (BD Biosciences,
Shanghai, China) and dried overnight. All the cell lines
(5 × 105) were incubated at 37 °C for 48 h before staining
with crystal violet. A set of images was acquired by using
NIS Elements image analysis software (Nikon, Tokyo,
Japan). The values for invasion were obtained by averaging
over three fields of view per well from a three replicate set
of samples for each experimental condition [15].
Cell-proliferation assay
Cells were seeded into 96-well plates (1.0 × 104 cells per
well). Cell viability was assessed by cell-counting kit-8
assay (Beyotime Institute of Biotechnology, Shanghai,
China). The absorbance of each well was monitored by a
spectrophotometer (Thermo, Shanghai, China) at 450 nm
(A450). For each case, three independent experiments
were performed.
Apoptosis assay
Twenty-four hours after transfection with miR-325
mimics, NC, miR-325 inhibitor and inhibitor NC, the
apoptosis in cultured cells was analyzed using annexin V
labeling. An annexin V–APC labeled Apoptosis Detec-
tion Kit (Abcam, Shanghai, China) was used according
to the manufacturer's protocol.
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Western blot
All the proteins were extracted from cultured cells,
quantitated using a protein assay (bicinchoninic acid
[BCA] method; Beyotime, Shanghai, China). Proteins
were fractionated by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis, transferred to polyvinylidene
fluoride (PVDF) membrane, blocked in 5 % dry milk at
room temperature for 1.5 h, and immunostained with
primary anti-HMGB1 (1:1000, Sigma, Shanghai, China)
and anti-GAPDH (1:5000, Kangchen, Shanghai, China).
All results were visualized through a chemiluminescent
detection system (Pierce ECL Substrate Western blot de-
tection system, Thermo, Pittsburgh, PA) and then exposed
in Molecular Imager ChemiDoc XRS System. The inte-
grated density of the band was quantified by Image soft-
ware (Bio-Rad, Hercules, CA).
Transient transfection and Luciferase assay
Both oligonucleotides miR-325 mimics and hsa-miR-325
inhibitor (anti-miR-325) were purchased from GenePharma
(Shanghai, China) along with NC (miR-control) and inhibi-
tor NC (anti-miR-control). HepG2 and Huh7 cells were
seeded into 6-well plates and transfected with 100 nM
siRNA/HMGB1 and siRNA/control (GenePharma,
Shanghai, China) using Lipofectamine 2000 (Invitrogen,
NY, USA) at a final concentration of 100 nM. The transfec-
tion efficiency was monitored by using qRT-PCR. For the
luciferase reporter assay, cells were cultured in 96 well
plates and transfected with luciferase reporters (50 ng), and
50 nM of miR-control, miR-325 mimics or miR-325-mut.
After 48 h, luciferase activity was measured using dual-
luciferase reporter system (Promega, USA). The renilla ac-
tivity was used as an internal control. Each transfection was
performed in triplicate.
Statistical methods
All values are expressed as mean ± SEM. Statistical ana-
lysis was performed using STAT10 and GraphPad Prism
(version 5.01; GraphPad Software, Inc, La Jolla, CA) stat-
istical software. The chi-squared test was used to test
the significance of observed differences in the Table 1
data and the t-test was used for the other data analyses.
The p values less than 0.05 were considered significant.
Results
The miR-325 is reduced and HMGB1 is elevated in HCC
tissues
First, we detected the expression levels of miR-325 and
HMGB1 in HCC specimens (n = 99) as compared with












NO. 99 51 48 49 50
Age(years) 0.832 0.565
<60 43 21 22 23 20
≥60 56 28 28 26 30
Gender 0.713 0.442
Male 46 24 22 25 21
Female 53 26 27 24 29
Histology 0.523 0.718
AC 45 23 22 21 24
SCC 54 28 26 27 27
Tumor size 0.003* 0.001*
T1/T2 46 17 29 35 11
T3/T4 53 37 16 18 35
TNM stage 0.001* 0.000*
I-II 48 10 38 36 12
III-IV 51 35 16 10 41
Metastasis 0.000* 0.000*
Yes 33 27 6 4 29
No 66 23 43 45 21
amedian = 0.5115
bmedian = 3.0011
*denotes p value < 0.05
AC: adenocarcinoma; SCC: squamous cell carcinoma; HCC: hepatocellular carcinoma
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corresponding adjacent tissues (n = 99) by using qRT-
PCR. Significantly, we discovered that lower miR-325 (p <
0.05; Fig. 1a) and higher HMGB1 (p < 0.05; Fig. 1a) mRNA
levels were expressed in HCC tissues than those in adja-
cent tissues. All patients were divided into two groups
using median RNA level of miR-325 (amedian = 0.5115)
and HMGB1 (bmedian = 3.0011) as threshold, respectively.
We found that the expression of miR-325 was negatively
correlated with HMGB1 expression (R = −0.4725; p =
0.0003) in cancer samples (Fig. 1b). The expression of
miR-325 was highly associated with HCC tumor size,
TNM stage and metastasis of patients (Table 1), which
suggests that that miR-325 may play an important role in
the pathogenesis of HCC.
Prognostic implications of miR-325 expression in HCC
To detect the prognostic implications of miR-325 expres-
sion in Overall Survival and Progression-free Survival of
HCC, detailed clinical information of all 99 HCC patients
in high miR-325 expression and low miR-325 expression
Fig. 1 miR-325 is decreased and inversely relates to HMGB1 expression in HCC patients. a Box-plot analysis of miR-325 and HMGB1 levels in 99
HCC patient samples and corresponding adjacent tissues. T refers to tumor tissues and P refers to corresponding adjacent tissues. b A negative
correlation was found between RNA expression of miR-325 and HMGB1 in tumor samples (P < 0.0001). c Kaplan–Meier overall and progression-free
survival curves for liver cancer patients with high and low miR-325 expression. Liver cancer patients with low miR-325 expression had significantly
shorter overall (P < 0.05) and progression-free (P < 0.05) survival than those with high miR-325 expression did. Data were shown as mean ± SEM of
three independent experiments. * indicates P < 0.05
Table 2 Univariate and multivariate analysis of overall survival in HCC patients (n = 99)
Variables Univariate analysis Multivariate analysis
HR 95 % CI p value HR 95 % CI p value
Age 1.461 0.811-2.627 0.193 1.513 0.790-2.631 0.178
Gender 1.029 0.586-1.792 0.941 0.967 0.533-1.798 0.876
Histology 1.022 0.556-1.796 0.913 1.047 0.569-1.892 0.823
TNM Stage 1.934 1.123-3.454 0.019* 1.920 1.092-3.394 0.023*
miR-325 expression 1.731 1.000-3.128 <0.050* 1.952 1.101-3.476 0.021*
*:p<0.05 was considered significant
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Fig. 2 (See legend on next page.)
Li et al. Diagnostic Pathology  (2015) 10:117 Page 5 of 11
groups was evaluated. Kaplan-Meier analysis demon-
strated that HCC patients with lower miR-325 expression
had significantly shorter Overall (P < 0.05, Fig. 1c) and
Progression-free (P < 0.05, Fig. 1c) Survival than those
with higher miR-325 expression. Moreover, the univariate
analysis revealed that both the TNM stage (P = 0.019)
and low miR-325 expression (P < 0.05) predicted poorer
overall survival of HCC patients. Furthermore, the
multivariate analyses identified clinical stage (P = 0.023)
and miR-325 expression (P = 0.021) in HCC as
(See figure on previous page.)
Fig. 2 Aberrant expression of miR-325 regulates HCC cell lines invasion. a Expression of miR-325 was analyzed in five liver cancer cell lines
(SMMC-7721, Hep3B, HepG2, Huh7 and Bel7404) and normal liver tissue (LO2). b The results of miR-325 expression in cell lines transfected with
miR-325 mimics, miR-325 inhibitor, control for miR-mimics (NC) and control for miR-325 inhibitor (inhibitor NC) were validated by using qRT-PCR.
c Transwell assay was performed according to the Material and Methods. HepG2 and Huh7 were treated with miR-325 mimics, miR-325 inhibitor,
NC and inhibitor NC for 24 h. The representative images of invasive cells at the bottom of the membrane stained with crystal violet were visualized as
shown. The quantifications of cell invasion were presented as percentage of cell numbers. Data are shown as mean ± SEM of three independent
experiments. * indicates significant difference compared with control group (P < 0.05)
Fig. 3 miR-325 inhibits cell proliferation. a Absorbance at 490 nm was presented for HepG2 (left) and Huh7 (right), respectively. b Flow cytometry
assay was used to analysis cell lines apoptosis. HepG2 (left) and Huh7 (right) * indicates P < 0.05
Li et al. Diagnostic Pathology  (2015) 10:117 Page 6 of 11
independent prognostic factors for overall survival of
HCC patients (Table 2).
miR-325 inhibits HCC cell invasion
Next, to clarify the role of miR-325 in HCC, we performed
a transwell invasion assay in vitro. First, we analyzed miR-
325 expression in five HCC cell lines (SMMC-7721,
Hep3B, HepG2, Huh7 and Bel7404) as compared with a
normal liver cell line (LO2) by using qRT-PCR assay. The
assay showed that miR-325 level in those cancer cell lines
was significantly downregulated compared with normal
control (Fig. 2a). Among those cancer cells, HepG2 showed
the lowest expression of miR-325 while miR-325 was high-
est in Huh7 (Fig. 2a). Based on this expression pattern, we
chose the HepG2 and Huh7 liver cancer cells to explore
the functions of miR-325 in HCC. The cell lines were trans-
fected with NC (mimics negative control), miR-325 mimics,
inhibitor NC and miR-325 inhibitor respectively. The effi-
ciency of transfection was examined by using qRT-PCR
assay (Fig. 2b). We found that up-regulation of miR-325
inhibited cell invasion (Fig. 2c). In addition, down-
regulation of miR-325 expression promoted the invasive
ability of HCC cell lines (Fig. 2c). These results suggested
that the abnormal expression level of miR-325 may be cap-
able of regulating HCC cell invasion.
Aberrant expression of miR-325 regulates cell proliferation
in vitro
In order to detect the functional roles of miR-325, we fur-
ther investigated the effect of miR-325 on proliferation by
using CCK8 assay. The assay showed differences on prolif-
eration after manipulation of miR-325 in both HepG2 and
Huh7 cells at 12-h, 24-h, 48-h and 72-h (Fig. 3a). In both
HepG2 and Huh7 cells, the proliferation was repressed in
miR-325 mimics expressed cells, whereas downregulation
of miR-325 expression had the reverse effect (Fig. 3a). In
addition, we used flow cytometry analysis to examine
whether miR-325 was involved in apoptosis. However, the
Fig. 4 HMGB1 was the direct targets of miR-325. a The potential miR-325 seed region at the 3'-UTR of HMGB1 mRNA was predicted by using
multiple bioinformatics analyses. HepG2 cells were co-transfected with miR-325 mimics (or NC) with pGL3-HMGB1 (or pGL3-HMGB1-mut) vector.
Luciferase activity was normalized by the ratio of firefly and Renilla luciferase signals. b HMGB1 mRNA and protein expression levels in HepG2 (left)
and Huh7 (right) cells transfected with NC, miR-325 mimics, inhibitor NC and miR-325 inhibitor were detected by using qRT-PCR and western-blotting.
GAPDH was regarded as an internal control. Data are shown as mean ± SEM of three independent experiments. * indicates significant difference
compared with control group (P < 0.05)
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assay showed that miR-325 did not affect apoptosis as
compared with the control (Fig. 3b). These results indi-
cated that aberrant expression of miR-325 could regulate
cell proliferation but have no effect on apoptosis in HCC
cell lines.
HMGB1 was the direct targets of miR-325
Since miR-325 contributed to the development of HCC,
we next set out to determine the potential mechanism in
which miR-325 could affect cell proliferation and inva-
sion in HCC cell lines. Based on the regulation pattern
of miRNAs in human carcinoma, we explored the candi-
date genes which have been reported to be associated
with cell invasion as well as regulated by microRNAs.
We then predicated the potential target genes of miR-
325 by using different bioinformatics analysis,
microRNA.org (http://www.microrna.org/microrna/),
miRDB (http://mirdb.org/miRDB/), and TargetScan
(http://www.targetscan.org/) database. Finally, bioinfor-
matic software indicated that 3'-UTR (untranslated re-
gion) of HMGB1 binds to miR-325 with the high score
(mirSVR score: -1.1355). The predicted binding of miR-
325 with HMGB1 3’UTR is illustrated in Fig. 4a (top
panel). To further explore whether the suppression of
HMGB1 expression induced by introducing miR-325
mimics was due to the binding of miR-325 to the 3'-
UTR of HMGB1, we cloned the 3'-UTR fragment con-
taining the predicted binding sites into pGL3 luciferase
reporter vector (pGL3-HMGB1) according to the predic-
tion. In the predicted target site, the 3ʹ-UTR fragment
with mutant sequence was also cloned (pGL3-HMGB1-
MUT) (Fig. 4a, top panel). The luciferase reporter assay
Fig. 5 Down-regulation of HMGB1 by siRNA partially reverses the promotion of cell invasion and proliferation induced by miR-325 inhibition.
a The transfection efficiency was validated by using western-blotting for both HepG2 and Huh7 cells transfected with miR-325 inhibitor and
inhibitor + siRNA/HMGB1 (the co-transfection cells of miR-325 inhibitor and siRNA/HMGB1) and inhibitor + siRNA/control (co-transfected with miR-325
inhibitor and siRNA/control). GAPDH was used as a control. Averages of three independent experiments were shown in the histogram (right panel).
b Absorbance at 490 nm was presented with Mean ± SEM. HepG2 (left) and Huh7 (right). c Transwell assay was performed as described in Material and
Methods. Cells were treated with miR-325 inhibitor and inhibitor + siRNA/HMGB1 (the co-transfection cells of miR-325 inhibitor and siRNA/HMGB1) and
inhibitor + siRNA/control (co-transfected with miR-325 inhibitor and siRNA/control) for 24 h. The representative images of invasive cells stained with
crystal violet were shown at the bottom. * indicates P < 0.05
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showed remarkably reduced activity with miR-325
mimics and pGL3-HMGB1 vectors as compared with
the control and all the mutant types (Fig. 4a, bottom
panel). Moreover, to further confirm that miR-325 influ-
enced HMGB1 expression, we performed qRT-PCR and
western blot analyses. The results showed that in both
mRNA and protein levels, up-regulation of miR-325 de-
creased HMGB1 expression; on the other hand, inhib-
ition of miR-325 raised HMGB1 levels (Fig. 4b). These
results suggested that miR-325 modulates HMGB1 ex-
pression by directly targeting its 3'-UTR.
Down-regulation of HMGB1 by siRNA partially reverses
the promotion of cell invasion and proliferation induced
by down-regulated miR-325
Furthermore, to explore whether the functional effect of
miR-325 on HCC cell lines was dependent on HMGB1,
we performed a rescue experiment. In the previous
study, HMGB1 was increased in cells transfected with
miR-325 inhibitor. So, we used RNA interference to si-
lence the expression of HMGB1. In vitro, cell lines were
co-transfected with miR-325 inhibitor and siRNA/
HMGB1. The transfection cells with miR-325 inhibitor
and the co-transfection cells with both miR-325 inhibi-
tor and siRNA/control were regarded as the control
groups. The western blot assay was used to examine the
transfection efficiency (Fig. 5a). Furthermore, both the
CCK8 assay and transwell invasion assay showed that
down-regulation of HMGB1 partially attenuated the in-
vasion and proliferation induced by miR-325 inhibition
as shown in Fig. 5b and c, respectively. These results
suggested that HMGB1 downregulation may potentially
reverse the adverse effect induced by miR-325 inhibition.
Discussion
In this study, we have demonstrated that HCCs have a sig-
nificantly different miR-325 expression profile when
compared to normal hepatocellular cells. Accumulating
evidence suggests that deregulation of miRNAs has been
frequently observed in tumor tissues. These miRNAs have
regulatory roles in the pathogenesis of cancer [16, 17]. In-
deed, patients with liver cancer often exhibit tumor
cell invasion and metastasis before diagnosis, which
renders current treatments including surgery, radio-
therapy, or chemotherapy ineffective. Therefore,
studying the molecular basis of liver cancer is crucial
for designing new therapeutic agents to improve the
survival rate.
The miRNAs can bind target mRNAs at complemen-
tary sites in their 3'-untranslated regions (3'-UTRs),
thereby suppressing the expression of the target gene at
the posttranscriptional level. Through this mechanism,
miRNAs regulate a wide range of biological processes
[18]. For example, miR-545 suppresses cell proliferation
by targeting Cyclin D1 and CDK4 [19]. The miRNAs
can also predict the prognosis of patients with various
cancers and may be a potential prognostic marker for
cancers [20–22]. It was shown that the microRNA-125b
inhibits the tumorigenic properties of HCC cells and
may serve as a prognostic biomarker [23]. Up-regulation
of microRNA-183-3p is a potent prognostic marker for
lung adenocarcinoma of female non-smokers [24]. miR-
10b expression was an independent prognostic factor in
lung cancer patients [25]. Shiiba et al. showed that miR-
325 might play a role in head and neck squamous cell
carcinoma [26]. In addition, Tang et al. suggested that
the miR-325 may potentially function as a prognostic
marker for prostate cancer [27]. To date, very few re-
ports have demonstrated the role of miR-325 and its as-
sociation with tumor characteristics especially for HCC.
In a microRNA expression profiling study, Wong et al.
implied that miR-325 might be involved in HCC malig-
nancy [28]. However, the exact or potential mechanisms
have not been investigated. Here we showed that the ex-
pression of miR-325 was significantly decreased in HCC
tissues (Fig. 1). Aberrant expression of miR-325 was re-
lated to the invasion and proliferation of HCC cell lines
(HepG2 and Huh7) in vitro. Patients with low miR-325
expression had poorer survival than those with high
miR-325 expression. Furthermore, we also found that
miR-325 overexpression diminished but miR-325 knock-
down increased HMGB1 expression level in HCC cell
lines by directly binding to the 3'-UTR of HMGB1. Simi-
larly, we tried to elucidate the reverse regulation of miR-
325 and HMGB1 within HCC, but we are unsure
whether miR-325 has other targets related to HCC prolif-
eration and invasion. These results suggested that changes
in the development of HCC should not be attributed to al-
ternations of one or a small number of genes. As the limit
on the number of HCC samples and cell types, more elab-
orate studies will be necessary for further exploration of
the link between miR-325 and HMGB1 and potential roles
of miR-325 in tumorigenesis.
HMGB1 is initially defined as chromatin-related pro-
tein with high acidic and basic amino acid content [29].
A recent study reported that HMGB1 modifies the inter-
action of DNA with transcription factors like p53 steroid
hormone receptors by non-specifically binding to a
smaller groove of DNA, and this is related to DNA repair,
transcription, differentiation, extracellular signalization,
and somatic recombination [30]. Evidence supporting the
role of HMGB1 in cancer progression, angiogenesis, in-
vasion, and metastasis development has been steadily
accumulating [31]. Existing studies suggest that
HMGB1 may have an important role in tumor progres-
sion beyond cancer development. The association of
HMGB1 overexpression with lymph node metastasis,
advanced stage in head-neck, esophagus squamous cell
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carcinoma, and cervix uteri has been demonstrated
[32–34]. All their findings supported the view that
HMGB1 may function as an oncogene. Here, we found
that HMGB1 was overexpressed in HCC samples and
associated with metastasis. Furthermore, we found that
silencing HMGB1 by siRNA partially abolished the en-
hancement of cells invasion and proliferation induced
by down-regulation of miR-325. These results implied
that the functional effect of miR-325 on HCC was
dependent on HMGB1.
An accurate prognosis is essential, particularly in ma-
lignant diseases, to provide advice to patients and guid-
ance for assessment and treatment. Clinical evaluation
and therapeutic decisions in HCC is complex because
they depend on both the grade of cancer spread (tumor
staging) and residual liver function (chronic liver disease
stage). A majority of patients with HCC are diagnosed at
a late stage, and only a small percentage fit resection or
transplantation criteria. Although well-defined and gen-
erally accepted staging systems are available for almost
all cancers, HCC is an exception, with many different
staging systems globally introduced to accommodate
each stratum of the disease [35–37]. Thus, an accurate
predictor of prognosis and a sensible selection criterion
that can be applied to patients with HCC, particularly
with early stage HCC, for rational treatment decisions
remains a challenging task. The miR-325 signature iden-
tified in this study significantly correlates with survival
of patients with HCC with relatively small tumors who
might be at an early stage of this disease. In contrast, the
clinical HCC staging systems were unable to distinguish
the outcome of these patients in this cohort. Our results
suggest that the miR-325 signature may be a useful tool
to classify patients with HCC assisting in their diagnosis
and improving clinical outcome.
Conclusions
In conclusion, we here provide evidence that reduced
expression of miR-325 may contribute to cell prolifera-
tion and invasion in HCC by directly targeting HMGB1.
Moreover, miR-325 was frequently downregulated in
HCC and decrease in miR-325 was significantly corre-
lated with poor prognosis of patients with HCC., there-
fore miR-325 might be utilized as a diagnostic marker in
future.
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